Blueprint Medicines

Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat.

Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data revolution: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.

Blueprint Medicines headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Bioinformatics sector. The company focuses on Biotechnology and has secured $341.0B in funding across 144 round(s). With a team of 501-1000 employees, Blueprint Medicines is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Blueprint Medicines, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.